TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06049368
Drug: 68Ga-P16-093
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 68Ga-P16-093 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of glioma by PET/CT.
Study: NCT05591651
Drug: Treatment of damaged nipple skin: Neutral preparation without hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The neutral preparation, containing only white vaseline, will be applied for five days, locally on the damaged nipple skin after every second breastfeeding session, and at least four times in 24 hours, alternating it with breast milk.
Study: NCT04843579
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given as 60 mg oral capsule
Study: NCT04843579
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given as 4 mg oral capsule
Study: NCT04843579
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given as 40 mg oral capsule
Study: NCT05157945
Drug: ALTO-300 PO Tablet
Normalized name: Altoprev
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet daily
Study: NCT05163223
Drug: rhuGM-CSF
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Q3W, 3 cycles, Plus a booster at 24weeks post the third vaccination, Intradermal injection
Study: NCT05163223
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Q3W; IV infusion
Study: NCT05625581
Drug: tofacitinib
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All subjects were treated immediately after non randomized enrollment. The treatment scheme of the experimental group: glucocorticoid+tropitib; the treatment scheme of the control group: glucocorticoid+cyclophosphamide.
Study: NCT05408247
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2400mg/day
Study: NCT04955249
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in this group receive dexmedetomidine-supplemented patient-controlled analgesia for up to 3 days after surgery. The formula is a mixture of dexmedetomidine (1 microgram/ml) and sufentanil (1 microgram/ml), diluted with normal saline to 200 ml. The analgesic pump is programmed to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
Study: NCT00899587
Drug: enalapril
Normalized name: Enalapril
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: enalapril 5 mg every night
Study: NCT05387967
Drug: Sacubitril/valsartan
Normalized name: SACUBITRIL/VALSARTAN
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All the recruited patients were prescribed Sacubitril/Valsartan at a starting dose of 50 (24/26) mg BID which was up-titrated, over the period of initial 6 weeks, to the maximum tolerated dose up to 200 (97/103) mg BID and further followed for a total of 12 weeks.
Study: NCT05445856
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methadone is administered as a single intravenous dose after induction of anesthesia and prior to initiation of surgery
Study: NCT01351168
Drug: Zolpidem first dose
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zolpidem will be given at 10 mg on randomized testing day. The randomization is such that the first dose of Zolpidem given to any subject will always be 10 mg
Study: NCT01351168
Drug: Zolpidem second dose
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zolpidem will be given at 7.5mg or 15 mg depending on the response from the first zolpidem dose.
Study: NCT01351168
Drug: sugar pill
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a sugar pill (placebo) will all be given orally in identical capsules to the other study drugs
Study: NCT05646992
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Used as daily immunosuppression. Started at 3mg twice daily (PO) on post-operative Day 1, adjusted to achieve serum trough concentrations of 8-10ng/ml.
Study: NCT05646992
Drug: Imuran
Normalized name: Imuran
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Used as daily immunosuppresion. 100 mg for total body weight less than 75 kg and 150 mg for total body weight greater than or equal to 75 mgs
Study: NCT05106205
Drug: DA-5213 10mg
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration (one tablet once a day)
Study: NCT04763226
Drug: BMS-986308
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT04763226
Drug: Furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05406700
Drug: Resection/Treatment with Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The participants in both arms will resume/start on treatment with niraparib 2 -4 weeks after surgery.~Treatment can be held for an additional 28 days to allow for recovery from surgery, at the investigator's discretion. Participants will continue treatment for up to 12 total cycles of treatment or until tumor progression, unacceptable toxicity or withdrawal of consent.
Study: NCT06199895
Drug: Paclitaxel Polymeric Micelles for Injection
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300mg/m2 of Paclitaxel Polymeric Micelles for Injection is intravenously administrated for ≥ 3 hours without special infusion device. The frequency of administration is once every 3 weeks (Q3W), and 3 weeks constitutes a treatment cycle.
Study: NCT04850664
Drug: CBOT + TAU
Normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The CBOT with proprietary odorant molecules is designed to stimulate olfactory neural activity over long periods of time. It is paired with OFC-dependent cognitive tasks.
Study: NCT04850664
Drug: Sham + TAU
Normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham CBOT device uses artificially scented compressed room air instead of olfactory stimulants and has control cognitive tasks.
Study: NCT05304455
Drug: Apixaban 2.5 MG
Normalized name: apixaban 2.5 MG
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.
Study: NCT05304455
Drug: Dipyridamole 25Mg Tab
Normalized name: DIPYRIDAMOLE 25MG TAB
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.
Study: NCT06106841
Drug: 400mg of TQB3909 tablets
Normalized name: magnesium hydroxide
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TQB3909 tablets 400mg, TQB3909 tablets is a B-cell lymphoma (BCL)-2 inhibitor.
Study: NCT06106841
Drug: 600mg of TQB3909 tablets
Normalized name: aluminum hydroxide
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3909 tablets 600mg, TQB3909 tablets is a B-cell lymphoma (BCL)-2 inhibitor.
Study: NCT06267144
Drug: Sintilimab plus chemotherapy
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab: 200 mg via intravenous infusion on Day 1 of each 21-day cycle for 2-3 cycles in the neoadjuvant therapy and the maintenance therapy.~Chemotherapy drugs: carboplatin/cisplatin+Pemetrexed/gemcitabine/albuminpaclitaxel.~Carboplatin: AUC 5 via intravenous infusion, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly.~Cisplatin: 75 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly.~Pemetrexed: 500mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly.~Gemcitabine:1.0g/m2 via intravenous infusion in day1 and day8, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly. Albuminpaclitaxel: 260 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly.
Study: NCT05145543
Drug: Levobupivacaine Hydrochloride
Normalized name: Levobupivacaine Hydrochloride
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25 % levobupivacaine (5 ml) will be applied.
Study: NCT05145543
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone plus levobupivacaine (5 ml) will be applied.
Study: NCT05392647
Drug: Hetrombopag
Normalized name: Hetrombopag
DrugBank: Hetrombopag (DB16184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All eligible patients were given hetrombopag orally at an initial dose of 5 mg once daily after overnight fasting (\>8 hours of fasting) and at least 2 hours before a meal . The dose of hetrombopag could be modified on the basis of the platelet count of patients after 2 weeks of administration.
Study: NCT00022945
Drug: Iodine-131 Anti-B1 Antibody
Normalized name: Iodine-131 anti-b1 antibody
DrugBank: Tositumomab I-131 (DB17991)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05280405
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab
Study: NCT05435053
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Every 2 weeks (3 mg/kg, maximum of 240 mg) for up to 24 weeks~Nivolumab is an immune checkpoint inhibitor (PD-1-inhibitor).
Study: NCT05262751
Drug: Nintedanib formulation 1
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nintedanib formulation 1: Monolithic Nintedanib Modified Release Tablet (MR1) as two Prototypes (MR1-1 and MR1-2).
Study: NCT05262751
Drug: Nintedanib formulation 2
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nintedanib formulation 2: Polyox Nintedanib Modified Release Tablet (MR2) as two Prototypes (MR2-1 and MR2-2).
Study: NCT05631704
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam will be administered in the highest dose cohort in Part 2 (Cohorts 8 or 9).
Study: NCT06319794
Drug: Bimiralisib
Normalized name: Bimiralisib
DrugBank: Bimiralisib (DB14846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be instructed to self-apply topical bimiralisib gel on the treatment area once daily for 2 weeks
Study: NCT06319794
Drug: Bimiralisib
Normalized name: Bimiralisib
DrugBank: Bimiralisib (DB14846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be instructed to self-apply topical bimiralisib gel on the treatment area once daily for 4 weeks
Study: NCT05693467
Drug: Dexamethasone palmitate emulsion(DXP) plus ropivacaine
Normalized name: palmitate
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The local infiltration solution in the dexamethasone palmitate emulsion(DXP) plus ropivacaine group will consist of ropivacaine and dexamethasone palmitate emulsion(DXP). For local infiltration, a total of 30mL solution will be prepared for each group, which will include 2mL of DXP(4mg per 1mL) added to 20.5 mL of saline and 7.5mL of 1% ropivacaine added to 15mL of saline for Group A . The surgeon will perform incision infiltration before the skin incision. A total of 10 mL of solution will be injected into each level. The study solution will be injected into the entire thickness of the planned incision site. The epidural space and intrathecal space will not be infiltrated.
Study: NCT06339294
Drug: Clotrimazole Cream
Normalized name: Clotrimazole Cream
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single time application of clotrimazole ointment was done after aural toilet in external auditory canal via IV catheter
Study: NCT05078671
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: olaparib treatment
Study: NCT05078671
Drug: Cobicistat
Normalized name: Cobicistat
DrugBank: Cobicistat (DB09065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmacokinetic booster
Study: NCT06339294
Drug: Povidone-Iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gelfoam soaked pyodine solution was placed in external auditory canal after aural toilet
Study: NCT06379542
Drug: XC8
Normalized name: Xylazine
DrugBank: Xylazine (DB11477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day or 80 mg/day for 7-14 days
Study: NCT06196580
Drug: repaglinide; midazolam; SHR4640
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: repaglinide; midazolam; SHR4640
Study: NCT06196580
Drug: repaglinide; midazolam; SHR4640; SHR4640 placebo
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: repaglinide; midazolam; SHR4640; SHR4640 placebo
Study: NCT06196580
Drug: repaglinide; midazolam; SHR4640 placebo
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: repaglinide; midazolam; SHR4640 placebo
Study: NCT05299255
Drug: Utidelone
Normalized name: Utidelone
DrugBank: Utidelone (DB17575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Utidelone Versus placebo in Third-line and above treatment of Extensive Small-cell Lung Cancer
Study: NCT05391360
Drug: Freethiadine tablets(part I)
Normalized name: iobenguane I-131
DrugBank: Furethidine (DB01464)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive either a single dose of Freethiadine on Day 1 only (SAD HV), twice daily dosing of Freethiadine starting on Day 1 through Day 10 (MAD HV)
Study: NCT05391360
Drug: entecavir tablets
Normalized name: Entecavir Tablets
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: once daily for consecutive 28 days
Study: NCT04827134
Drug: TRIUMEQ
Normalized name: Triumeq
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TRIUMEQ will be available as fixed dose combination (FDC) dispersible tablets to be administered orally as a dispersion.
Study: NCT04827134
Drug: DOVATO
Normalized name: Dovato
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: DOVATO will be available as FDC dispersible tablets to be administered orally as a dispersion.
Study: NCT04843267
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab in first-line treatment of Hodgkin's lymphoma
Study: NCT05675813
Drug: CHOP+selinexor+5-Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase I: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. If tumor NGS indicates T1 genetic subtype, for the remaining 5 cycles, they will receive 5-Azacitidine ih d-7-d-1 and selinexor 40mg or 60mg qw (d-7, 1, 8) by traditional 3+3 dose escalation methods and decide RP2D of selinexor.~Phase II: Patients will receive CHOP for the first cycle. If tumor NGS indicates T1 genetic subtype, then 1:1 randomized to experimental (CHOPX2) or standard CHOP regimen for 5 cycles of every 21-day cycle.
Study: NCT05675813
Drug: CHOP+duvelisib+5-Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase I: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. If tumor NGS indicates T2 genetic subtype, for the remaining 5 cycles, they will receive 5-Azacitidine ih d-7-d-1 and duvelisib 25mg or 50mg bid (d1-14) by traditional 3+3 dose escalation methods and decide RP2D of duvelisib.~Phase II: Patients will receive CHOP for the first cycle. If tumor NGS indicates T1 genetic subtype, then 1:1 randomized to experimental (CHOPX2) or standard CHOP regimen for 5 cycles of every 21-day cycle.
Study: NCT05675813
Drug: CHOP+chidamide+tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. If tumor NGS indicates T3 genetic subtype, for the remaining 5 cycles, they will receive tislelizumab 200mg d0 ivgtt and chidamide 20mg or 30mg biw (d1,4,8,11) by traditional 3+3 dose escalation methods and decide RP2D of chidamide.~Phase II: Patients will receive CHOP for the first cycle. If tumor NGS indicates T3 genetic subtype, then 1:1 randomized to experimental (CHOPX2) or standard CHOP regimen for 5 cycles of every 21-day cycle.
Study: NCT02172001
Drug: Iron isomaltoside 1000
Normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00430833
Drug: candesartan
Normalized name: Candesartan
DrugBank: Candesartan (DB13919)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05555147
Drug: nerve block with 0.5% ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After general anesthesia, the patients will receive bilateral infraorbital and infratrochlear nerve block 30 minutes prior to surgery. Infraorbital nerve block is performed while using an extraoral approach. A 25-gauge needle was inserted laterally to the ipsilateral nostril after palpating the infraorbital ridge to locate the infraorbital foramen. The index finger of the non-dominant hand was positioned above the infraorbital foramen, and the needle was advanced until it was felt beneath the finger. 2 ml of the 0.5% ropivacaine slowly injected after negative aspiration of blood was confirmed. Inserting the needle 1 cm above the inner canthus, targeting the junction of the orbit and the nasal bone, performed infratrochlear nerve block. After negative aspiration of blood, 1 ml of the 0.5% ropivacaine was injected. Contralateral nerve block was performed in the same manner.
Study: NCT05918276
Drug: Orelabrutinib and BG
Normalized name: Orelabrutinib
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Orelabrutinib Orelabrutinib 200mg, po, qd，C2-C7. Twenty-eight days for a cycle.~Drug: BG Bendamustin 70mg/m2, IV, d2\&d3 inC1, and then d1\&d2 inC2-6.Twenty-eight days for a cycle.~Obintuzumab 100mg IV, d1, 900mg d2, 1000mg d8\&d15 in C1, and then 1000mg/m2 IV, d1 in C2-6. Twenty-eight days for a cycle.
Study: NCT05168462
Drug: Reduced noradrenaline use
Normalized name: noradrenaline hydrochloride
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced noradrenaline by using a lower MAP target
Study: NCT06207370
Drug: Tafenoquine
Normalized name: tafenoquine
DrugBank: Tafenoquine (DB06608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Tafenoquine
Study: NCT06330935
Drug: Tranexamic Acid (TXA)
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 patients will be randomized to A arm and 30 patients to B arm
Study: NCT04797507
Drug: SHR-1210 plus Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1210: a novel anti-PD-1 antibody Anlotinib: a multi-kinase inhibitor
Study: NCT05780086
Drug: 30% icodextrin and 10% dextrose
DrugBank: Icodextrin (DB00702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dwell time of 24 hours using a 500 ml sodium-free peritoneal dialysis solution based on 30% icodextrin and 10% dextrose
Study: NCT04606901
Drug: neostigmine/glycopyrrolate
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: neuromuscular blockade reversal agents
Study: NCT04606901
Drug: sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: neuromuscular blockade reversal agent
Study: NCT05634148
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexmedetomidine will be administered 45 minutes before extubation in intervention group
Study: NCT00002068
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002068
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05010876
Drug: C1 Inhibitor Human
Normalized name: C1 inhibitor human
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard care + 1000 units of C1 inhibitor during 2 slow infusions of 500 units
Study: NCT05010876
Drug: Icatibant Injection
Normalized name: Icatibant Injection
DrugBank: Icatibant (DB06196)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: a single injection of 30 mg subcutaneously
Study: NCT04716751
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant treatment stage: Toripalimab 240mg, Carboplatin AUC5+ paclitaxel 200 mg/m ², iv, 3 weeks per cycle, 2-4 cycles in total; Surgical treatment stage: Patients with tracheal malignant tumor received radical surgery after neoadjuvant therapy, and patients who could not or refused surgical treatment due to various reasons were treated with multidisciplinary discussion.~Adjuvant treatment stage: Toripalimab 240mg, Carboplatin AUC5+ paclitaxel 200 mg/m ²,iv, up to 4 cycles (including neoadjuvant stage).
Study: NCT05372107
Drug: AG-80308
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG-80308 Eye Drop Solution